Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 480

1.

[Molecular biology of sarcoma and therapeutic choices.]

Dufresne A, Cassier P, Heudel P, Pissaloux D, Wang Q, Blay JY, Ray-Coquard I.

Bull Cancer. 2015 Jan 13. pii: S0007-4551(14)00006-X. doi: 10.1016/j.bulcan.2014.12.005. [Epub ahead of print] Review. French.

PMID:
25609490
[PubMed - as supplied by publisher]
2.

[Major advances in oncology in 2014: The editorial board of the Bulletin du Cancer point of view.]

Massard C, Bay JO, André T, Blay JY, Goncalves A, Orbach D, Wislez M, Thariat J, Magné N, Vignot S.

Bull Cancer. 2015 Jan 9. pii: S0007-4551(14)00013-7. doi: 10.1016/j.bulcan.2014.11.002. [Epub ahead of print] Review. French.

PMID:
25609486
[PubMed - as supplied by publisher]
3.

Disequilibrium of BMP2 Levels in the Breast Stem Cell Niche Launches Epithelial Transformation by Overamplifying BMPR1B Cell Response.

Chapellier M, Bachelard-Cascales E, Schmidt X, Clément F, Treilleux I, Delay E, Jammot A, Ménétrier-Caux C, Pochon G, Besançon R, Voeltzel T, Caron de Fromentel C, Caux C, Blay JY, Iggo R, Maguer-Satta V.

Stem Cell Reports. 2015 Jan 15. pii: S2213-6711(14)00384-1. doi: 10.1016/j.stemcr.2014.12.007. [Epub ahead of print]

PMID:
25601208
[PubMed - as supplied by publisher]
Free Article
4.

Clinical trial designs for rare diseases: Studies developed and discussed by the International Rare Cancers Initiative.

Bogaerts J, Sydes MR, Keat N, McConnell A, Benson A, Ho A, Roth A, Fortpied C, Eng C, Peckitt C, Coens C, Pettaway C, Arnold D, Hall E, Marshall E, Sclafani F, Hatcher H, Earl H, Ray-Coquard I, Paul J, Blay JY, Whelan J, Panageas K, Wheatley K, Harrington K, Licitra L, Billingham L, Hensley M, McCabe M, Patel PM, Carvajal R, Wilson R, Glynne-Jones R, McWilliams R, Leyvraz S, Rao S, Nicholson S, Filiaci V, Negrouk A, Lacombe D, Dupont E, Pauporté I, Welch JJ, Law K, Trimble T, Seymour M.

Eur J Cancer. 2014 Dec 23. pii: S0959-8049(14)01063-6. doi: 10.1016/j.ejca.2014.10.027. [Epub ahead of print] Review.

PMID:
25542058
[PubMed - as supplied by publisher]
Free Article
5.

Classification of current anticancer immunotherapies.

Galluzzi L, Vacchelli E, Bravo-San Pedro JM, Buqué A, Senovilla L, Baracco EE, Bloy N, Castoldi F, Abastado JP, Agostinis P, Apte RN, Aranda F, Ayyoub M, Beckhove P, Blay JY, Bracci L, Caignard A, Castelli C, Cavallo F, Celis E, Cerundolo V, Clayton A, Colombo MP, Coussens L, Dhodapkar MV, Eggermont AM, Fearon DT, Fridman WH, Fučíková J, Gabrilovich DI, Galon J, Garg A, Ghiringhelli F, Giaccone G, Gilboa E, Gnjatic S, Hoos A, Hosmalin A, Jäger D, Kalinski P, Kärre K, Kepp O, Kiessling R, Kirkwood JM, Klein E, Knuth A, Lewis CE, Liblau R, Lotze MT, Lugli E, Mach JP, Mattei F, Mavilio D, Melero I, Melief CJ, Mittendorf EA, Moretta L, Odunsi A, Okada H, Palucka AK, Peter ME, Pienta KJ, Porgador A, Prendergast GC, Rabinovich GA, Restifo NP, Rizvi N, Sautès-Fridman C, Schreiber H, Seliger B, Shiku H, Silva-Santos B, Smyth MJ, Speiser DE, Spisek R, Srivastava PK, Talmadge JE, Tartour E, Van Der Burg SH, Van Den Eynde BJ, Vile R, Wagner H, Weber JS, Whiteside TL, Wolchok JD, Zitvogel L, Zou W, Kroemer G.

Oncotarget. 2014 Dec 30;5(24):12472-508.

PMID:
25537519
[PubMed - in process]
Free Article
6.

The off-label use of targeted therapies in sarcomas: the OUTC'S program.

Eberst L, Cropet C, Le Cesne A, Pautier P, Penel N, Adenis A, Chevreau C, Bay JO, Collard O, Cupissol D, Duffaud F, Gentet JC, Piperno-Neumann S, Marec-Berard P, Bompas E, Thyss A, Chaigneau L, Cassier P, Bertucci F, Blay JY, Ray-Coquard I.

BMC Cancer. 2014 Nov 24;14:870. doi: 10.1186/1471-2407-14-870.

PMID:
25420707
[PubMed - in process]
Free PMC Article
7.

Transferability of health cost evaluation across locations in oncology: cluster and principal component analysis as an explorative tool.

Perrier L, Buja A, Mastrangelo G, Baron P, Ducimetière F, Pauwels PJ, Rossi C, Gilly F, Martin A, Favier B, Farsi F, Laramas M, Baldo V, Collard O, Cellier D, Blay JY, Ray-Coquard I.

BMC Health Serv Res. 2014 Nov 18;14(1):537. [Epub ahead of print]

PMID:
25399725
[PubMed - as supplied by publisher]
Free PMC Article
8.

Assessing the multimodal management of advanced solitary fibrous tumors of the pleura in a routine practice setting.

Bylicki O, Rouvière D, Cassier P, Chalabreysse L, Levard A, Maury JM, Margery J, Blay JY, Mazières J, Girard N.

J Thorac Oncol. 2015 Feb;10(2):309-15. doi: 10.1097/JTO.0000000000000401.

PMID:
25319181
[PubMed - in process]
9.

Tumor genotype is an independent prognostic factor in primary gastrointestinal stromal tumors of gastric origin: a european multicenter analysis based on ConticaGIST.

Wozniak A, Rutkowski P, Schöffski P, Ray-Coquard I, Hostein I, Schildhaus HU, Le Cesne A, Bylina E, Limon J, Blay JY, Siedlecki JA, Wardelmann E, Sciot R, Coindre JM, Debiec-Rychter M.

Clin Cancer Res. 2014 Dec 1;20(23):6105-16. doi: 10.1158/1078-0432.CCR-14-1677. Epub 2014 Oct 7.

PMID:
25294914
[PubMed - in process]
10.

Doxorubicin-based adjuvant chemotherapy in soft tissue sarcoma: pooled analysis of two STBSG-EORTC phase III clinical trials.

Le Cesne A, Ouali M, Leahy MG, Santoro A, Hoekstra HJ, Hohenberger P, Van Coevorden F, Rutkowski P, Van Hoesel R, Verweij J, Bonvalot S, Steward WP, Gronchi A, Hogendoorn PC, Litiere S, Marreaud S, Blay JY, Van Der Graaf WT.

Ann Oncol. 2014 Dec;25(12):2425-32. doi: 10.1093/annonc/mdu460. Epub 2014 Oct 6.

PMID:
25294887
[PubMed - in process]
11.

Rare Cancers Europe (RCE) methodological recommendations for clinical studies in rare cancers: a European consensus position paper.

Casali PG, Bruzzi P, Bogaerts J, Blay JY; on behalf of the Rare Cancers Europe (RCE) Consensus Panel.

Ann Oncol. 2015 Feb;26(2):300-306. Epub 2014 Oct 1. Review.

PMID:
25274616
[PubMed - as supplied by publisher]
Free Article
12.

Etoposide and carbo-or cisplatin combination therapy in refractory or relapsed Ewing sarcoma: a large retrospective study.

van Maldegem AM, Benson C, Rutkowski P, Blay JY, van den Berg H, Placzke J, Rasper M, Judson I, Juergens H, Dirksen U, Gelderblom H.

Pediatr Blood Cancer. 2015 Jan;62(1):40-4. doi: 10.1002/pbc.25230. Epub 2014 Sep 22.

PMID:
25251256
[PubMed - in process]
13.

Impact of KIT exon 10 M541L allelic variant on the response to imatinib in aggressive fibromatosis: analysis of the desminib series by competitive allele specific Taqman PCR technology.

Dufresne A, Alberti L, Brahmi M, Kabani S, Philippon H, Pérol D, Blay JY.

BMC Cancer. 2014 Aug 29;14:632. doi: 10.1186/1471-2407-14-632.

PMID:
25174682
[PubMed - in process]
Free PMC Article
14.

Dsh homolog DVL3 mediates resistance to IGFIR inhibition by regulating IGF-RAS signaling.

Gao S, Bajrami I, Verrill C, Kigozi A, Ouaret D, Aleksic T, Asher R, Han C, Allen P, Bailey D, Feller S, Kashima T, Athanasou N, Blay JY, Schmitz S, Machiels JP, Upile N, Jones TM, Thalmann G, Ashraf SQ, Wilding JL, Bodmer WF, Middleton MR, Ashworth A, Lord CJ, Macaulay VM.

Cancer Res. 2014 Oct 15;74(20):5866-77. doi: 10.1158/0008-5472.CAN-14-0806. Epub 2014 Aug 28.

PMID:
25168481
[PubMed - indexed for MEDLINE]
15.

Masitinib in advanced gastrointestinal stromal tumor (GIST) after failure of imatinib: a randomized controlled open-label trial.

Adenis A, Blay JY, Bui-Nguyen B, Bouché O, Bertucci F, Isambert N, Bompas E, Chaigneau L, Domont J, Ray-Coquard I, Blésius A, Van Tine BA, Bulusu VR, Dubreuil P, Mansfield CD, Acin Y, Moussy A, Hermine O, Le Cesne A.

Ann Oncol. 2014 Sep;25(9):1762-9. doi: 10.1093/annonc/mdu237. Epub 2014 Jul 25.

PMID:
25122671
[PubMed - in process]
Free PMC Article
16.

Pazopanib in advanced desmoplastic small round cell tumours: a multi-institutional experience.

Frezza AM, Benson C, Judson IR, Litiere S, Marreaud S, Sleijfer S, Blay JY, Dewji R, Fisher C, van der Graaf W, Hayward L.

Clin Sarcoma Res. 2014 Jul 29;4:7. doi: 10.1186/2045-3329-4-7. eCollection 2014.

PMID:
25089183
[PubMed]
Free PMC Article
17.

Lack of correlation of BTNL2 polymorphism and cancer risk in sarcoidosis. BTNL2 and cancer risk in sarcoidosis.

Gaillot-Drevon M, Calender A, Blay JY, Valeyre D, Israel-Biet D, Roy P, Pacheco Y.

Sarcoidosis Vasc Diffuse Lung Dis. 2014 Jul 8;31(2):136-41.

PMID:
25078641
[PubMed - in process]
18.

Response to chemotherapy is not related to chromosome instability in synovial sarcoma.

Chakiba C, Lagarde P, Pissaloux D, Neuville A, Brulard C, Pérot G, Coindre JM, Terrier P, Ranchere-Vince D, Ferrari A, Collini P, Suurmeijer AJ, Blay JY, Terrisse SA, Piperno-Neumann S, Averous G, Bui B, Orbach D, Italiano A, Chibon F.

Ann Oncol. 2014 Nov;25(11):2267-71. doi: 10.1093/annonc/mdu362. Epub 2014 Jul 28.

PMID:
25070544
[PubMed - in process]
19.

Guidelines for time-to-event end point definitions in sarcomas and gastrointestinal stromal tumors (GIST) trials: results of the DATECAN initiative (Definition for the Assessment of Time-to-event Endpoints in CANcer trials)†

Bellera CA, Penel N, Ouali M, Bonvalot S, Casali PG, Nielsen OS, Delannes M, Litière S, Bonnetain F, Dabakuyo TS, Benjamin RS, Blay JY, Bui BN, Collin F, Delaney TF, Duffaud F, Filleron T, Fiore M, Gelderblom H, George S, Grimer R, Grosclaude P, Gronchi A, Haas R, Hohenberger P, Issels R, Italiano A, Jooste V, Krarup-Hansen A, Le Péchoux C, Mussi C, Oberlin O, Patel S, Piperno-Neumann S, Raut C, Ray-Coquard I, Rutkowski P, Schuetze S, Sleijfer S, Stoeckle E, Van Glabbeke M, Woll P, Gourgou-Bourgade S, Mathoulin-Pélissier S.

Ann Oncol. 2014 Jul 28. pii: mdu360. [Epub ahead of print] Review.

PMID:
25070543
[PubMed - as supplied by publisher]
20.

Going further in the knowledge of Yondelis®; what's new in clinical trials?

Blay JY.

Future Oncol. 2014 Jun;10(8 Suppl):s7-s12. doi: 10.2217/fon.14.114.

PMID:
25048046
[PubMed - in process]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk